Biotech RadarJobs updated

Trial and FDA signals

106 signals at 90 companies: 47 new trials with clinical-operations roles open, 25 drug approvals and 7 device approvals with manufacturing, quality or commercial roles open, and 27 FDA complete response letters. Every row links to its ClinicalTrials.gov or FDA source and gives its date.

Job counts are as of the check date. “Since then posted” counts only jobs Radar can show were first posted after the event date; otherwise the row says how many matching roles are open. A trial or FDA event listed next to open jobs does not mean one caused the other. Each row’s evidence lists the source passage and record ID. Trials count only when the company is the lead sponsor and the start date is an actual date. Data checked Oct 18, 2026. All dated changes · Ownership changes.

New trial + clinical hiring (47)

CompanySignalEvent dateSource
IpsenStarted a Phase 3 trial (NCT07779252, actual start Aug 25, 2026); 22 clinical-operations roles open.
Evidence (1 event)
  • Aug 25, 2026 · ClinicalTrials.gov NCT07779252
    leadSponsor.name='Ipsen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-25,type:ACTUAL}; studyFirstPostDate=2026-08-21; briefTitle='A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between '
Aug 25, 2026ClinicalTrials.gov NCT07779252
AstraZenecaStarted a Phase 3 trial (NCT07816666, actual start Sep 24, 2026) (+23 other new trials); 85 clinical-operations roles open.
Evidence (24 events)
  • Sep 24, 2026 · ClinicalTrials.gov NCT07816666
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-24,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07686120
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-07-07; briefTitle='A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.'
  • Sep 16, 2026 · ClinicalTrials.gov NCT07851025
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-16,type:ACTUAL}; studyFirstPostDate=2026-10-01; briefTitle='Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial O'
  • Sep 15, 2026 · ClinicalTrials.gov NCT07711002
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-15,type:ACTUAL}; studyFirstPostDate=2026-07-17; briefTitle="Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy With"
  • Sep 10, 2026 · ClinicalTrials.gov NCT07619118
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-06-01; briefTitle='A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholestero'
  • Sep 1, 2026 · ClinicalTrials.gov NCT07624305
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-06-03; briefTitle='A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07751848
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-07; briefTitle='A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07691970
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-07-09; briefTitle='Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Conti'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07776509
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07761117
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF'
  • Aug 21, 2026 · ClinicalTrials.gov NCT07753993
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.'
  • Aug 21, 2026 · ClinicalTrials.gov NCT07775404
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabe'
  • Aug 20, 2026 · ClinicalTrials.gov NCT07784270
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight'
  • Aug 19, 2026 · ClinicalTrials.gov NCT07784725
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-19,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabet'
  • Aug 12, 2026 · ClinicalTrials.gov NCT07619131
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-12,type:ACTUAL}; studyFirstPostDate=2026-06-01; briefTitle='A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT'
  • Jul 24, 2026 · ClinicalTrials.gov NCT07444567
    leadSponsor.name='AstraZeneca'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-24,type:ACTUAL}; studyFirstPostDate=2026-03-03; briefTitle='Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatme'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07630714
    leadSponsor.name='AstraZeneca'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-06-05; briefTitle='A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years '
  • Jul 27, 2026 · ClinicalTrials.gov NCT07681596
    leadSponsor.name='AstraZeneca'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07824622
    leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-09-17; briefTitle='Study of Safety and PK of AZD0543 in Healthy Adults'
  • Aug 6, 2026 · ClinicalTrials.gov NCT07754331
    leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-06,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin'
  • Jul 30, 2026 · ClinicalTrials.gov NCT07685600
    leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants'
  • Jul 27, 2026 · ClinicalTrials.gov NCT07723833
    leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle='A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants'
  • Jul 23, 2026 · ClinicalTrials.gov NCT06951880
    leadSponsor.name='AstraZeneca'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-23,type:ACTUAL}; studyFirstPostDate=2025-04-30; briefTitle='A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers'
  • Sep 5, 2026 · ClinicalTrials.gov NCT07718724
    leadSponsor.name='AstraZeneca'; phases=['NA']; overallStatus=RECRUITING; startDateStruct={date:2026-09-05,type:ACTUAL}; studyFirstPostDate=2026-07-22; briefTitle='Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist'
Sep 24, 2026ClinicalTrials.gov NCT07816666
AlconStarted a Phase 3 trial (NCT07531043, actual start Sep 30, 2026) (+1 other new trial); 2 clinical-operations roles open.
Evidence (2 events)
  • Sep 30, 2026 · ClinicalTrials.gov NCT07531043
    leadSponsor.name='Alcon Research'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-30,type:ACTUAL}; studyFirstPostDate=2026-04-15; briefTitle='Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults'
  • Sep 27, 2026 · ClinicalTrials.gov NCT07578363
    leadSponsor.name='Alcon Research'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-27,type:ACTUAL}; studyFirstPostDate=2026-05-11; briefTitle='An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults'
Sep 30, 2026ClinicalTrials.gov NCT07531043
Keros TherapeuticsStarted a Phase 2 trial (NCT07704099, actual start Sep 25, 2026); since then posted 1 clinical-operations role.
Evidence (1 event)
  • Sep 25, 2026 · ClinicalTrials.gov NCT07704099
    leadSponsor.name='Keros Therapeutics, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-07-15; briefTitle='Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy'
Sep 25, 2026ClinicalTrials.gov NCT07704099
Iovance BiotherapeuticsStarted a Phase 2 trial (NCT07741877, actual start Oct 2, 2026); 2 clinical-operations roles open.
Evidence (1 event)
  • Oct 2, 2026 · ClinicalTrials.gov NCT07741877
    leadSponsor.name='Iovance Biotherapeutics, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-10-02,type:ACTUAL}; studyFirstPostDate=2026-08-03; briefTitle='A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma'
Oct 2, 2026ClinicalTrials.gov NCT07741877
Zydus TherapeuticsStarted a Phase 3 trial (NCT07424677, actual start Aug 11, 2026); 2 clinical-operations roles open.
Evidence (1 event)
  • Aug 11, 2026 · ClinicalTrials.gov NCT07424677
    leadSponsor.name='Zydus Therapeutics Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-11,type:ACTUAL}; studyFirstPostDate=2026-02-20; briefTitle='Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy'
Aug 11, 2026ClinicalTrials.gov NCT07424677
GileadStarted a Phase 2/3 trial (NCT07708727, actual start Jul 29, 2026) (+2 other new trials); 55 clinical-operations roles open.
Evidence (3 events)
  • Jul 29, 2026 · ClinicalTrials.gov NCT07708727
    leadSponsor.name='Gilead Sciences'; phases=['PHASE2', 'PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-29,type:ACTUAL}; studyFirstPostDate=2026-07-16; briefTitle='Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment'
  • Aug 7, 2026 · ClinicalTrials.gov NCT07546812
    leadSponsor.name='Gilead Sciences'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-07,type:ACTUAL}; studyFirstPostDate=2026-04-23; briefTitle='Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ'
  • Jul 22, 2026 · ClinicalTrials.gov NCT07719491
    leadSponsor.name='Gilead Sciences'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-22,type:ACTUAL}; studyFirstPostDate=2026-07-22; briefTitle='Study of GS-0415 and How It Works in People With HIV'
Jul 29, 2026ClinicalTrials.gov NCT07708727
AbbVieStarted a Phase 3 trial (NCT07772492, actual start Aug 24, 2026) (+12 other new trials); 73 clinical-operations roles open.
Evidence (13 events)
  • Aug 24, 2026 · ClinicalTrials.gov NCT07772492
    leadSponsor.name='AbbVie'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-19; briefTitle='A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata'
  • Aug 19, 2026 · ClinicalTrials.gov NCT07794878
    leadSponsor.name='AbbVie'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-19,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Fol'
  • Sep 1, 2026 · ClinicalTrials.gov NCT07744126
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-08-04; briefTitle='A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembroliz'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07769502
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-18; briefTitle='A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Particip'
  • Aug 4, 2026 · ClinicalTrials.gov NCT07752979
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2026-08-07; briefTitle='Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07697456
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle="Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis"
  • Jul 22, 2026 · ClinicalTrials.gov NCT07730554
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-22,type:ACTUAL}; studyFirstPostDate=2026-07-28; briefTitle='A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Par'
  • Sep 14, 2026 · ClinicalTrials.gov NCT07807956
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-14,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With '
  • Aug 26, 2026 · ClinicalTrials.gov NCT07843693
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-09-28; briefTitle='A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers'
  • Aug 20, 2026 · ClinicalTrials.gov NCT07071532
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2025-07-17; briefTitle='A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With B'
  • Aug 10, 2026 · ClinicalTrials.gov NCT07756580
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-10,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07736638
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-30; briefTitle='A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants'
  • Sep 9, 2026 · ClinicalTrials.gov NCT07794891
    leadSponsor.name='AbbVie'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='Study to Assess Participant Satisfaction After Jawline and Neck Treatment'
Aug 24, 2026ClinicalTrials.gov NCT07772492
BeOne MedicinesStarted a Phase 2 trial (NCT07733180, actual start Sep 14, 2026) (+3 other new trials); 53 clinical-operations roles open.
Evidence (4 events)
  • Sep 14, 2026 · ClinicalTrials.gov NCT07733180
    leadSponsor.name='BeOne Medicines'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-14,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC'
  • Sep 25, 2026 · ClinicalTrials.gov NCT07820891
    leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-09-15; briefTitle='A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395'
  • Sep 2, 2026 · ClinicalTrials.gov NCT07746141
    leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-08-04; briefTitle='A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic So'
  • Jul 21, 2026 · ClinicalTrials.gov NCT07712640
    leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-21,type:ACTUAL}; studyFirstPostDate=2026-07-17; briefTitle='A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in '
Sep 14, 2026ClinicalTrials.gov NCT07733180
NovartisStarted a Phase 3 trial (NCT07811869, actual start Oct 7, 2026) (+14 other new trials); 30 clinical-operations roles open.
Evidence (15 events)
  • Oct 7, 2026 · ClinicalTrials.gov NCT07811869
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-07,type:ACTUAL}; studyFirstPostDate=2026-09-10; briefTitle='A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin '
  • Sep 21, 2026 · ClinicalTrials.gov NCT07816328
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-21,type:ACTUAL}; studyFirstPostDate=2026-09-11; briefTitle='Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately '
  • Sep 1, 2026 · ClinicalTrials.gov NCT07625306
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=WITHDRAWN; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-06-04; briefTitle='Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07768371
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A 52-week Study of Remibrutinib in IgE-mediated Food Allergy'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07700056
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin ('
  • Aug 6, 2026 · ClinicalTrials.gov NCT07498335
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-06,type:ACTUAL}; studyFirstPostDate=2026-03-27; briefTitle='Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN'
  • Aug 4, 2026 · ClinicalTrials.gov NCT05776927
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2023-03-20; briefTitle='A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol '
  • Sep 29, 2026 · ClinicalTrials.gov NCT07775924
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-29,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus'
  • Sep 18, 2026 · ClinicalTrials.gov NCT07830719
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-09-21; briefTitle='Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07737743
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-07-30; briefTitle="A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease"
  • Aug 4, 2026 · ClinicalTrials.gov NCT07421167
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2026-02-19; briefTitle="A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients "
  • Jul 30, 2026 · ClinicalTrials.gov NCT07681271
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea '
  • Sep 8, 2026 · ClinicalTrials.gov NCT07801508
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-09-03; briefTitle='A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors'
  • Sep 2, 2026 · ClinicalTrials.gov NCT07783503
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participan'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07448610
    leadSponsor.name='Novartis Pharmaceuticals'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-03-04; briefTitle='ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-br'
Oct 7, 2026ClinicalTrials.gov NCT07811869
Eli LillyStarted a Phase 3 trial (NCT07817875, actual start Sep 25, 2026) (+19 other new trials); 39 clinical-operations roles open.
Evidence (20 events)
  • Sep 25, 2026 · ClinicalTrials.gov NCT07817875
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Yea'
  • Aug 26, 2026 · ClinicalTrials.gov NCT07794579
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Ob'
  • Aug 14, 2026 · ClinicalTrials.gov NCT07775300
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-14,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07783802
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event'
  • Aug 12, 2026 · ClinicalTrials.gov NCT07641504
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-12,type:ACTUAL}; studyFirstPostDate=2026-06-11; briefTitle='A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain'
  • Aug 7, 2026 · ClinicalTrials.gov NCT07759245
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-07,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)'
  • Sep 22, 2026 · ClinicalTrials.gov NCT07808073
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-22,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy'
  • Sep 15, 2026 · ClinicalTrials.gov NCT07808060
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-15,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight'
  • Sep 11, 2026 · ClinicalTrials.gov NCT07803744
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-11,type:ACTUAL}; studyFirstPostDate=2026-09-04; briefTitle='A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity'
  • Sep 9, 2026 · ClinicalTrials.gov NCT07787169
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-08-26; briefTitle="A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease"
  • Sep 2, 2026 · ClinicalTrials.gov NCT07801300
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-09-03; briefTitle='A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)'
  • Sep 2, 2026 · ClinicalTrials.gov NCT07818967
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='A Study of Abemaciclib (LY2835219) in Healthy Participants'
  • Aug 28, 2026 · ClinicalTrials.gov NCT07794592
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-28,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07767487
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A Study of LY4226695 in Healthy Participants'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07765498
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-14; briefTitle='A Study of LY4355756 in Healthy Participants'
  • Aug 11, 2026 · ClinicalTrials.gov NCT07547540
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-11,type:ACTUAL}; studyFirstPostDate=2026-04-23; briefTitle='A Study of LY3971297 in Participants With Heart Failure'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07738614
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-07-31; briefTitle='A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight'
  • Jul 20, 2026 · ClinicalTrials.gov NCT07707375
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-07-16; briefTitle='A Study of LY4268989 (MORF 057) in Healthy Participants'
  • Jul 20, 2026 · ClinicalTrials.gov NCT07701083
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-07-14; briefTitle='A Study of Eloralintide (LY3841136) in Healthy Participants'
  • Aug 5, 2026 · ClinicalTrials.gov NCT07612267
    leadSponsor.name='Eli Lilly and Company'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-08-05,type:ACTUAL}; studyFirstPostDate=2026-05-28; briefTitle='A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indicat'
Sep 25, 2026ClinicalTrials.gov NCT07817875
Jazz PharmaceuticalsStarted a Phase 2/3 trial (NCT07723963, actual start Sep 18, 2026); 6 clinical-operations roles open.
Evidence (1 event)
  • Sep 18, 2026 · ClinicalTrials.gov NCT07723963
    leadSponsor.name='Jazz Pharmaceuticals'; phases=['PHASE2', 'PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle='A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy'
Sep 18, 2026ClinicalTrials.gov NCT07723963
4D Molecular TherapeuticsStarted a Phase 3 trial (NCT07867080, actual start Sep 18, 2026); since then posted 2 clinical-operations roles.
Evidence (1 event)
  • Sep 18, 2026 · ClinicalTrials.gov NCT07867080
    leadSponsor.name='4D Molecular Therapeutics'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-10-09; briefTitle='A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).'
Sep 18, 2026ClinicalTrials.gov NCT07867080
Madrigal PharmaceuticalsStarted a Phase 2 trial (NCT07763015, actual start Aug 1, 2026) (+1 other new trial); 13 clinical-operations roles open.
Evidence (2 events)
  • Aug 1, 2026 · ClinicalTrials.gov NCT07763015
    leadSponsor.name='Madrigal Pharmaceuticals, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-01,type:ACTUAL}; studyFirstPostDate=2026-08-13; briefTitle='Study of Resmetirom in Children and Adolescents With MASH'
  • Oct 7, 2026 · ClinicalTrials.gov NCT07848191
    leadSponsor.name='Madrigal Pharmaceuticals, Inc.'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-10-07,type:ACTUAL}; studyFirstPostDate=2026-09-29; briefTitle='Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis'
Aug 1, 2026ClinicalTrials.gov NCT07763015
Atrium TherapeuticsStarted a Phase 1/2 trial (NCT07738107, actual start Sep 14, 2026); since then posted 1 clinical-operations role.
Evidence (1 event)
  • Sep 14, 2026 · ClinicalTrials.gov NCT07738107
    leadSponsor.name='Atrium Therapeutics'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-14,type:ACTUAL}; studyFirstPostDate=2026-07-31; briefTitle='ATR 1072 in Participants With PRKAG2 Syndrome'
Sep 14, 2026ClinicalTrials.gov NCT07738107
Viatris (2)Started a Phase 4 trial (NCT07813026, actual start Aug 3, 2026); 4 clinical-operations roles open.
Evidence (1 event)
  • Aug 3, 2026 · ClinicalTrials.gov NCT07813026
    leadSponsor.name='Viatris Inc.'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-08-03,type:ACTUAL}; studyFirstPostDate=2026-09-10; briefTitle='Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Us'
Aug 3, 2026ClinicalTrials.gov NCT07813026
Scholar Rock, Inc.Started a Phase 2 trial (NCT07435129, actual start Jul 30, 2026); since then posted 4 clinical-operations roles.
Evidence (1 event)
  • Jul 30, 2026 · ClinicalTrials.gov NCT07435129
    leadSponsor.name='Scholar Rock, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-02-27; briefTitle='Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD'
Jul 30, 2026ClinicalTrials.gov NCT07435129
KardiganStarted a Phase 3 trial (NCT07771465, actual start Aug 26, 2026); since then posted 6 clinical-operations roles.
Evidence (1 event)
  • Aug 26, 2026 · ClinicalTrials.gov NCT07771465
    leadSponsor.name='Kardigan, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-08-18; briefTitle='A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy'
Aug 26, 2026ClinicalTrials.gov NCT07771465
AmgenStarted a Phase 3 trial (NCT07778316, actual start Aug 28, 2026) (+5 other new trials); 102 clinical-operations roles open.
Evidence (6 events)
  • Aug 28, 2026 · ClinicalTrials.gov NCT07778316
    leadSponsor.name='Amgen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-28,type:ACTUAL}; studyFirstPostDate=2026-08-21; briefTitle='Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)'
  • Jul 29, 2026 · ClinicalTrials.gov NCT07684144
    leadSponsor.name='Amgen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-29,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)'
  • Jul 23, 2026 · ClinicalTrials.gov NCT07684235
    leadSponsor.name='Amgen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-23,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)'
  • Jul 21, 2026 · ClinicalTrials.gov NCT06987539
    leadSponsor.name='Amgen'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-21,type:ACTUAL}; studyFirstPostDate=2025-05-23; briefTitle='A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia '
  • Sep 22, 2026 · ClinicalTrials.gov NCT07811999
    leadSponsor.name='Amgen'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-22,type:ACTUAL}; studyFirstPostDate=2026-09-10; briefTitle='Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Inje'
  • Aug 7, 2026 · ClinicalTrials.gov NCT07745907
    leadSponsor.name='Amgen'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-07,type:ACTUAL}; studyFirstPostDate=2026-08-04; briefTitle='A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers'
Aug 28, 2026ClinicalTrials.gov NCT07778316
PfizerStarted a Phase 3 trial (NCT07794761, actual start Oct 2, 2026) (+17 other new trials); 15 clinical-operations roles open.
Evidence (18 events)
  • Oct 2, 2026 · ClinicalTrials.gov NCT07794761
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-02,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)'
  • Sep 30, 2026 · ClinicalTrials.gov NCT07845500
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-30,type:ACTUAL}; studyFirstPostDate=2026-09-29; briefTitle='A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overwe'
  • Sep 30, 2026 · ClinicalTrials.gov NCT07869043
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-30,type:ACTUAL}; studyFirstPostDate=2026-10-09; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma'
  • Sep 24, 2026 · ClinicalTrials.gov NCT07792954
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-24,type:ACTUAL}; studyFirstPostDate=2026-08-28; briefTitle='A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obes'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07823608
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-09-16; briefTitle='A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight o'
  • Sep 9, 2026 · ClinicalTrials.gov NCT07819097
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-09-14; briefTitle='A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07794748
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adu'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07768345
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults'
  • Aug 26, 2026 · ClinicalTrials.gov NCT07729462
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-07-27; briefTitle='A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine'
  • Aug 24, 2026 · ClinicalTrials.gov NCT07783425
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema'
  • Aug 20, 2026 · ClinicalTrials.gov NCT07772921
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2026-08-19; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07765888
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-14; briefTitle='A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema'
  • Jul 30, 2026 · ClinicalTrials.gov NCT07733765
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as '
  • Jul 25, 2026 · ClinicalTrials.gov NCT07754539
    leadSponsor.name='Pfizer'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-25,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Evaluate 20vPnC in Healthy Chinese Infants'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07792941
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-28; briefTitle='A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07731139
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-28; briefTitle='A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity'
  • Jul 23, 2026 · ClinicalTrials.gov NCT07725809
    leadSponsor.name='Pfizer'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-23,type:ACTUAL}; studyFirstPostDate=2026-07-24; briefTitle='A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity'
  • Jul 24, 2026 · ClinicalTrials.gov NCT07685769
    leadSponsor.name='Pfizer'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-07-24,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India'
Oct 2, 2026ClinicalTrials.gov NCT07794761
Merck & Co., Inc.Started a Phase 3 trial (NCT07743164, actual start Oct 7, 2026) (+13 other new trials); 93 clinical-operations roles open.
Evidence (14 events)
  • Oct 7, 2026 · ClinicalTrials.gov NCT07743164
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-07,type:ACTUAL}; studyFirstPostDate=2026-08-03; briefTitle='A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed Durin'
  • Sep 25, 2026 · ClinicalTrials.gov NCT07705607
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-07-15; briefTitle='A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)'
  • Sep 18, 2026 · ClinicalTrials.gov NCT07776691
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-18,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cance'
  • Aug 27, 2026 · ClinicalTrials.gov NCT07705555
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-07-15; briefTitle='A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)'
  • Oct 7, 2026 · ClinicalTrials.gov NCT07785609
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-10-07,type:ACTUAL}; studyFirstPostDate=2026-08-25; briefTitle='A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07646860
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-06-15; briefTitle='A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)'
  • Sep 10, 2026 · ClinicalTrials.gov NCT07743151
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-08-03; briefTitle='A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07734610
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)'
  • Aug 31, 2026 · ClinicalTrials.gov NCT07776665
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-20; briefTitle='A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)'
  • Aug 25, 2026 · ClinicalTrials.gov NCT07748351
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-08-25,type:ACTUAL}; studyFirstPostDate=2026-08-05; briefTitle='A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07595263
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-05-19; briefTitle='A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)'
  • Aug 14, 2026 · ClinicalTrials.gov NCT07677163
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=COMPLETED; startDateStruct={date:2026-08-14,type:ACTUAL}; studyFirstPostDate=2026-06-30; briefTitle='A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)'
  • Aug 12, 2026 · ClinicalTrials.gov NCT07712575
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-12,type:ACTUAL}; studyFirstPostDate=2026-07-17; briefTitle='A Study of V132 in Healthy Older Participants (V132-001)'
  • Jul 20, 2026 · ClinicalTrials.gov NCT07697625
    leadSponsor.name='Merck Sharp & Dohme LLC'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)'
Oct 7, 2026ClinicalTrials.gov NCT07743164
Corbus PharmaceuticalsStarted a Phase 3 trial (NCT07768189, actual start Sep 29, 2026); 2 clinical-operations roles open.
Evidence (1 event)
  • Sep 29, 2026 · ClinicalTrials.gov NCT07768189
    leadSponsor.name='Corbus Pharmaceuticals Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-29,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle="A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma"
Sep 29, 2026ClinicalTrials.gov NCT07768189
Bristol-Myers SquibbStarted a Phase 3 trial (NCT07680790, actual start Sep 8, 2026) (+5 other new trials); 73 clinical-operations roles open.
Evidence (6 events)
  • Sep 8, 2026 · ClinicalTrials.gov NCT07680790
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination W'
  • Sep 10, 2026 · ClinicalTrials.gov NCT07680764
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-07-02; briefTitle='A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT)'
  • Jul 27, 2026 · ClinicalTrials.gov NCT07492680
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-03-25; briefTitle='A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Hom'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07763418
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-08-13; briefTitle='A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease '
  • Aug 31, 2026 · ClinicalTrials.gov NCT07800897
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-09-02; briefTitle='A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants'
  • Aug 21, 2026 · ClinicalTrials.gov NCT07780383
    leadSponsor.name='Bristol-Myers Squibb'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-21; briefTitle='A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Heal'
Sep 8, 2026ClinicalTrials.gov NCT07680790
Alnylam PharmaceuticalsStarted a Phase 2 trial (NCT07636811, actual start Aug 17, 2026) (+1 other new trial); since then posted 18 clinical-operations roles.
Evidence (2 events)
  • Aug 17, 2026 · ClinicalTrials.gov NCT07636811
    leadSponsor.name='Alnylam Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-06-09; briefTitle="A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)"
  • Jul 30, 2026 · ClinicalTrials.gov NCT07575308
    leadSponsor.name='Alnylam Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-05-08; briefTitle='HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB'
Aug 17, 2026ClinicalTrials.gov NCT07636811
Regeneron PharmaceuticalsStarted a Phase 3 trial (NCT07697599, actual start Sep 7, 2026) (+9 other new trials); 101 clinical-operations roles open.
Evidence (10 events)
  • Sep 7, 2026 · ClinicalTrials.gov NCT07697599
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-07,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Centra'
  • Aug 26, 2026 · ClinicalTrials.gov NCT07493304
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-03-25; briefTitle='Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers'
  • Aug 10, 2026 · ClinicalTrials.gov NCT07626411
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-10,type:ACTUAL}; studyFirstPostDate=2026-06-04; briefTitle='Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07675811
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-06-30; briefTitle='A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctiviti'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07675824
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-06-30; briefTitle='REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07685808
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes'
  • Jul 20, 2026 · ClinicalTrials.gov NCT07594106
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-05-18; briefTitle='REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07759167
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07543055
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-04-21; briefTitle='A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Ha'
  • Oct 6, 2026 · ClinicalTrials.gov NCT07587658
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-10-06,type:ACTUAL}; studyFirstPostDate=2026-05-14; briefTitle='This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants Afte'
Sep 7, 2026ClinicalTrials.gov NCT07697599
Edwards LifesciencesStarted an interventional study with no drug phase (NCT07466745, actual start Jul 27, 2026); 20 clinical-operations roles open.
Evidence (1 event)
  • Jul 27, 2026 · ClinicalTrials.gov NCT07466745
    leadSponsor.name='Edwards Lifesciences'; phases=['NA']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-03-12; briefTitle='Autus Valve Continued Access Study (CAS)'
Jul 27, 2026ClinicalTrials.gov NCT07466745
Oruka TherapeuticsStarted a Phase 2 trial (NCT07783542, actual start Aug 21, 2026); since then posted 8 clinical-operations roles.
Evidence (1 event)
  • Aug 21, 2026 · ClinicalTrials.gov NCT07783542
    leadSponsor.name='Oruka Therapeutics, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-21,type:ACTUAL}; studyFirstPostDate=2026-08-24; briefTitle='ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa'
Aug 21, 2026ClinicalTrials.gov NCT07783542
MBX BiosciencesStarted a Phase 3 trial (NCT07699471, actual start Aug 26, 2026); since then posted 2 clinical-operations roles.
Evidence (1 event)
  • Aug 26, 2026 · ClinicalTrials.gov NCT07699471
    leadSponsor.name='MBX Biosciences'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism'
Aug 26, 2026ClinicalTrials.gov NCT07699471
Antares TherapeuticsStarted a Phase 1/2 trial (NCT07767474, actual start Aug 31, 2026); since then posted 1 clinical-operations role.
Evidence (1 event)
  • Aug 31, 2026 · ClinicalTrials.gov NCT07767474
    leadSponsor.name='Antares Therapeutics, Inc'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-08-17; briefTitle='A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors'
Aug 31, 2026ClinicalTrials.gov NCT07767474
Axsome TherapeuticsStarted a Phase 3 trial (NCT07766655, actual start Aug 27, 2026) (+1 other new trial); since then posted 3 clinical-operations roles.
Evidence (2 events)
  • Aug 27, 2026 · ClinicalTrials.gov NCT07766655
    leadSponsor.name='Axsome Therapeutics, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-27,type:ACTUAL}; studyFirstPostDate=2026-08-14; briefTitle='Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)'
  • Aug 6, 2026 · ClinicalTrials.gov NCT07773883
    leadSponsor.name='Axsome Therapeutics, Inc.'; phases=['PHASE3']; overallStatus=ENROLLING_BY_INVITATION; startDateStruct={date:2026-08-06,type:ACTUAL}; studyFirstPostDate=2026-08-19; briefTitle='An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD'
Aug 27, 2026ClinicalTrials.gov NCT07766655
Edgewise TherapeuticsStarted a Phase 2 trial (NCT07795814, actual start Aug 25, 2026); since then posted 2 clinical-operations roles.
Evidence (1 event)
  • Aug 25, 2026 · ClinicalTrials.gov NCT07795814
    leadSponsor.name='Edgewise Therapeutics, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-25,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)'
Aug 25, 2026ClinicalTrials.gov NCT07795814
Janux TherapeuticsStarted a Phase 1 trial (NCT07813637, actual start Sep 10, 2026); since then posted 1 clinical-operations role.
Evidence (1 event)
  • Sep 10, 2026 · ClinicalTrials.gov NCT07813637
    leadSponsor.name='Janux Therapeutics'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-09-10; briefTitle='Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC'
Sep 10, 2026ClinicalTrials.gov NCT07813637
Kodiak SciencesStarted a Phase 3 trial (NCT07734844, actual start Aug 3, 2026); 2 clinical-operations roles open.
Evidence (1 event)
  • Aug 3, 2026 · ClinicalTrials.gov NCT07734844
    leadSponsor.name='Kodiak Sciences Inc'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-03,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO'
Aug 3, 2026ClinicalTrials.gov NCT07734844
ModernaStarted a Phase 1 trial (NCT07764237, actual start Aug 11, 2026) (+1 other new trial); 12 clinical-operations roles open.
Evidence (2 events)
  • Aug 11, 2026 · ClinicalTrials.gov NCT07764237
    leadSponsor.name='ModernaTX, Inc.'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-11,type:ACTUAL}; studyFirstPostDate=2026-08-13; briefTitle='A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07737717
    leadSponsor.name='ModernaTX, Inc.'; phases=['PHASE1']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-07-30; briefTitle='A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Heal'
Aug 11, 2026ClinicalTrials.gov NCT07764237
Puma BiotechnologyStarted a Phase 2 trial (NCT07465757, actual start Sep 17, 2026); 1 clinical-operations role open.
Evidence (1 event)
  • Sep 17, 2026 · ClinicalTrials.gov NCT07465757
    leadSponsor.name='Puma Biotechnology, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-03-12; briefTitle='A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)'
Sep 17, 2026ClinicalTrials.gov NCT07465757
Verastem OncologyStarted a Phase 2 trial (NCT07659795, actual start Jul 28, 2026) (+1 other new trial); 3 clinical-operations roles open.
Evidence (2 events)
  • Jul 28, 2026 · ClinicalTrials.gov NCT07659795
    leadSponsor.name='Verastem, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-06-22; briefTitle='A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer'
  • Jul 22, 2026 · ClinicalTrials.gov NCT07659782
    leadSponsor.name='Verastem, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-22,type:ACTUAL}; studyFirstPostDate=2026-06-22; briefTitle='A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer'
Jul 28, 2026ClinicalTrials.gov NCT07659795
BiogenStarted a Phase 3 trial (NCT07444476, actual start Sep 8, 2026) (+2 other new trials); 19 clinical-operations roles open.
Evidence (3 events)
  • Sep 8, 2026 · ClinicalTrials.gov NCT07444476
    leadSponsor.name='Biogen'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-03-03; briefTitle="A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular At"
  • Jul 30, 2026 · ClinicalTrials.gov NCT07722546
    leadSponsor.name='Biogen'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-07-23; briefTitle="A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old"
  • Jul 21, 2026 · ClinicalTrials.gov NCT07662148
    leadSponsor.name='Biogen'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-21,type:ACTUAL}; studyFirstPostDate=2026-06-23; briefTitle='A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18'
Sep 8, 2026ClinicalTrials.gov NCT07444476
Vertex Pharmaceuticals IncorporatedStarted a Phase 3 trial (NCT07807995, actual start Sep 17, 2026) (+1 other new trial); 21 clinical-operations roles open.
Evidence (2 events)
  • Sep 17, 2026 · ClinicalTrials.gov NCT07807995
    leadSponsor.name='Vertex Pharmaceuticals Incorporated'; phases=['PHASE3']; overallStatus=ENROLLING_BY_INVITATION; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy'
  • Sep 1, 2026 · ClinicalTrials.gov NCT07792408
    leadSponsor.name='Vertex Pharmaceuticals Incorporated'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-08-28; briefTitle='Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives'
Sep 17, 2026ClinicalTrials.gov NCT07807995
ExelixisStarted a Phase 3 trial (NCT07620574, actual start Jul 30, 2026); 13 clinical-operations roles open.
Evidence (1 event)
  • Jul 30, 2026 · ClinicalTrials.gov NCT07620574
    leadSponsor.name='Exelixis'; phases=['PHASE3']; overallStatus=ENROLLING_BY_INVITATION; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-06-02; briefTitle='Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study'
Jul 30, 2026ClinicalTrials.gov NCT07620574
TakedaStarted a Phase 3 trial (NCT07623161, actual start Sep 10, 2026) (+1 other new trial); 39 clinical-operations roles open.
Evidence (2 events)
  • Sep 10, 2026 · ClinicalTrials.gov NCT07623161
    leadSponsor.name='Takeda'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-10,type:ACTUAL}; studyFirstPostDate=2026-06-03; briefTitle='A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib'
  • Aug 13, 2026 · ClinicalTrials.gov NCT07403968
    leadSponsor.name='Takeda'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-13,type:ACTUAL}; studyFirstPostDate=2026-02-11; briefTitle="A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease"
Sep 10, 2026ClinicalTrials.gov NCT07623161
Fate TherapeuticsStarted a Phase 2 trial (NCT07570862, actual start Jul 27, 2026); since then posted 1 clinical-operations role.
Evidence (1 event)
  • Jul 27, 2026 · ClinicalTrials.gov NCT07570862
    leadSponsor.name='Fate Therapeutics'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-05-06; briefTitle='A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis'
Jul 27, 2026ClinicalTrials.gov NCT07570862
Atavistik BioStarted a Phase 1/2 trial (NCT07601425, actual start Jul 27, 2026); 1 clinical-operations role open.
Evidence (1 event)
  • Jul 27, 2026 · ClinicalTrials.gov NCT07601425
    leadSponsor.name='Atavistik Bio, Inc'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-05-22; briefTitle='Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)'
Jul 27, 2026ClinicalTrials.gov NCT07601425
GaldermaStarted a Phase 3 trial (NCT07762833, actual start Oct 8, 2026); 11 clinical-operations roles open.
Evidence (1 event)
  • Oct 8, 2026 · ClinicalTrials.gov NCT07762833
    leadSponsor.name='Galderma R&D'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-10-08,type:ACTUAL}; studyFirstPostDate=2026-08-13; briefTitle='Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis'
Oct 8, 2026ClinicalTrials.gov NCT07762833
Neptune MedicalStarted an interventional study with no drug phase (NCT07606963, actual start Aug 24, 2026); 1 clinical-operations role open.
Evidence (1 event)
  • Aug 24, 2026 · ClinicalTrials.gov NCT07606963
    leadSponsor.name='Neptune Medical'; phases=['NA']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-05-26; briefTitle='Triton 1.5 Robotic System for Diagnostic Colonoscopy'
Aug 24, 2026ClinicalTrials.gov NCT07606963
argenxStarted a Phase 1 trial (NCT07610564, actual start Jul 27, 2026); 5 clinical-operations roles open.
Evidence (1 event)
  • Jul 27, 2026 · ClinicalTrials.gov NCT07610564
    leadSponsor.name='argenx'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-05-28; briefTitle='A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy'
Jul 27, 2026ClinicalTrials.gov NCT07610564
Nurix TherapeuticsStarted a Phase 3 trial (NCT07516093, actual start Aug 3, 2026); since then posted 7 clinical-operations roles.
Evidence (1 event)
  • Aug 3, 2026 · ClinicalTrials.gov NCT07516093
    leadSponsor.name='Nurix Therapeutics, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-03,type:ACTUAL}; studyFirstPostDate=2026-04-07; briefTitle='Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL'
Aug 3, 2026ClinicalTrials.gov NCT07516093
PulmovantStarted a Phase 3 trial (NCT07816185, actual start Aug 31, 2026); since then posted 5 clinical-operations roles.
Evidence (1 event)
  • Aug 31, 2026 · ClinicalTrials.gov NCT07816185
    leadSponsor.name='Pulmovant, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-31,type:ACTUAL}; studyFirstPostDate=2026-09-11; briefTitle='A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)'
Aug 31, 2026ClinicalTrials.gov NCT07816185

Drug approval + hiring (25)

CompanySignalEvent dateSource
AbbVieFDA novel approval for JUVMO (NDA 220415, Sep 25, 2026; +1 other approval); 585 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Sep 25, 2026 · FDA NDA 220415
    openFDA drugsfda: application_number=NDA220415; sponsor_name='ABBVIE'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260925; submission_class_code=TYPE 1; brand_name=['JUVMO', 'JUVMO (COPACKAGED)']
  • May 27, 2026 · FDA BLA 761460
    openFDA drugsfda: application_number=BLA761460; sponsor_name='ABBVIE INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260527; submission_class_code=TYPE 1; brand_name=['DECNUPAZ']
Sep 25, 2026FDA NDA 220415
Mirum PharmaceuticalsFDA novel approval for ATEBRIOZ (NDA 221198, Sep 25, 2026); since then posted 2 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Sep 25, 2026 · FDA NDA 221198
    openFDA drugsfda: application_number=NDA221198; sponsor_name='MIRUM'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260925; submission_class_code=TYPE 1; brand_name=['ATEBRIOZ']
Sep 25, 2026FDA NDA 221198
Elevar TherapeuticsFDA novel approval for LYRFIGTU (NDA 220425, Sep 23, 2026); 2 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Sep 23, 2026 · FDA NDA 220425
    openFDA drugsfda: application_number=NDA220425; sponsor_name='ELEVAR'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260923; submission_class_code=TYPE 1; brand_name=['LYRFIGTU']
Sep 23, 2026FDA NDA 220425
Eli LillyFDA novel approval for ONSWIK (BLA 761408, Sep 23, 2026; +1 other approval); 324 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Sep 23, 2026 · FDA BLA 761408
    openFDA drugsfda: application_number=BLA761408; sponsor_name='ELI LILLY AND CO'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260923; submission_class_code=TYPE 1; brand_name=['ONSWIK']
  • Apr 1, 2026 · FDA NDA 220934
    openFDA drugsfda: application_number=NDA220934; sponsor_name='ELI LILLY AND CO'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260401; submission_class_code=TYPE 1; brand_name=['FOUNDAYO']
Sep 23, 2026FDA BLA 761408
Scholar Rock, Inc.FDA novel approval for ISEMBYLD (BLA 761463, Sep 11, 2026); since then posted 3 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Sep 11, 2026 · FDA BLA 761463
    openFDA drugsfda: application_number=BLA761463; sponsor_name='SCHOLAR ROCK INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260911; submission_class_code=TYPE 1; brand_name=['ISEMBYLD']
Sep 11, 2026FDA BLA 761463
AstraZenecaFDA novel approval for ETCAMAH (NDA 220359, Sep 4, 2026; +3 other approvals); 605 manufacturing/quality or commercial roles open.
Evidence (4 events)
  • Sep 4, 2026 · FDA NDA 220359
    openFDA drugsfda: application_number=NDA220359; sponsor_name='ASTRAZENECA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260904; submission_class_code=TYPE 1; brand_name=['ETCAMAH']
  • May 15, 2026 · FDA NDA 219878
    openFDA drugsfda: application_number=NDA219878; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260515; submission_class_code=TYPE 1; brand_name=['BAXFENDY']
  • Oct 8, 2026 · FDA NDA 220290
    openFDA drugsfda: application_number=NDA220290; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20261008; submission_class_code=TYPE 5; brand_name=['BREZTRI AEROSPHERE']
  • Apr 24, 2026 · FDA BLA 761451
    openFDA drugsfda: application_number=BLA761451; sponsor_name='ASTRAZENECA AB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260424; submission_class_code=TYPE 5; brand_name=['SAPHNELO']
Sep 4, 2026FDA NDA 220359
TakedaFDA novel approval for MIMRYLO (NDA 220605, Aug 28, 2026; +1 other approval); 530 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Aug 28, 2026 · FDA NDA 220605
    openFDA drugsfda: application_number=NDA220605; sponsor_name='TAKEDA PHARMS AM'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260828; submission_class_code=TYPE 1; brand_name=['MIMRYLO']
  • Aug 5, 2026 · FDA NDA 220860
    openFDA drugsfda: application_number=NDA220860; sponsor_name='TAKEDA PHARMS USA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260805; submission_class_code=TYPE 1; brand_name=['ORZEYFUL']
Aug 28, 2026FDA NDA 220605
Regeneron PharmaceuticalsFDA novel approval for PASATRU (BLA 761508, Aug 19, 2026); 266 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Aug 19, 2026 · FDA BLA 761508
    openFDA drugsfda: application_number=BLA761508; sponsor_name='REGENERON PHARMACEUTICALS, INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260819; submission_class_code=TYPE 1; brand_name=['PASATRU']
Aug 19, 2026FDA BLA 761508
Bristol-Myers SquibbFDA novel approval for ZENBEXUS (NDA 221075, Aug 13, 2026); 378 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Aug 13, 2026 · FDA NDA 221075
    openFDA drugsfda: application_number=NDA221075; sponsor_name='BRISTOL MYERS SQUIBB'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260813; submission_class_code=TYPE 1; brand_name=['ZENBEXUS']
Aug 13, 2026FDA NDA 221075
Otsuka Pharmaceutical Co., Ltd.FDA novel approval for SIMTRIYO (NDA 218145, Jul 24, 2026; +1 other approval); 95 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Jul 24, 2026 · FDA NDA 218145
    openFDA drugsfda: application_number=NDA218145; sponsor_name='OTSUKA PHARMACEUTICAL CO LTD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260724; submission_class_code=TYPE 1; brand_name=['SIMTRIYO']
  • Nov 25, 2025 · FDA BLA 761434
    openFDA drugsfda: application_number=BLA761434; sponsor_name='OTSUKA PHARM CO LTD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251125; submission_class_code=TYPE 1; brand_name=['VOYXACT']
Jul 24, 2026FDA NDA 218145
NuvalentFDA novel approval for JIDEYTRO (NDA 220185, Jul 22, 2026); since then posted 2 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Jul 22, 2026 · FDA NDA 220185
    openFDA drugsfda: application_number=NDA220185; sponsor_name='NUVALENT'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260722; submission_class_code=TYPE 1; brand_name=['JIDEYTRO']
Jul 22, 2026FDA NDA 220185
Merck & Co., Inc.FDA novel approval for LIPFENDRA (NDA 220848, Jul 15, 2026; +1 other approval); 463 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Jul 15, 2026 · FDA NDA 220848
    openFDA drugsfda: application_number=NDA220848; sponsor_name='MSD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260715; submission_class_code=TYPE 1; brand_name=['LIPFENDRA']
  • Apr 20, 2026 · FDA NDA 216964
    openFDA drugsfda: application_number=NDA216964; sponsor_name='MSD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260420; submission_class_code=TYPE 1/4; brand_name=['IDVYNSO']
Jul 15, 2026FDA NDA 220848
Vera TherapeuticsFDA novel approval for TRUTAKNA (BLA 761486, Jul 7, 2026); since then posted 5 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Jul 7, 2026 · FDA BLA 761486
    openFDA drugsfda: application_number=BLA761486; sponsor_name='VERA THERAPEUTICS INC.'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260707; submission_class_code=TYPE 1; brand_name=['TRUTAKNA']
Jul 7, 2026FDA BLA 761486
ShionogiFDA novel approval for XOCOVA (NDA 220442, May 29, 2026); 29 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • May 29, 2026 · FDA NDA 220442
    openFDA drugsfda: application_number=NDA220442; sponsor_name='SHIONOGI'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260529; submission_class_code=TYPE 1; brand_name=['XOCOVA']
May 29, 2026FDA NDA 220442
GileadFDA novel approval for HEPCLUDEX (BLA 761468, May 22, 2026; +2 other approvals); 206 manufacturing/quality or commercial roles open.
Evidence (3 events)
  • May 22, 2026 · FDA BLA 761468
    openFDA drugsfda: application_number=BLA761468; sponsor_name='GILEAD SCIENCES INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260522; submission_class_code=TYPE 1; brand_name=['HEPCLUDEX']
  • Aug 27, 2026 · FDA NDA 221104
    openFDA drugsfda: application_number=NDA221104; sponsor_name='GILEAD SCIENCES INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260827; submission_class_code=TYPE 4; brand_name=['BIXLENVO']
  • Aug 27, 2026 · FDA NDA 221443
    openFDA drugsfda: application_number=NDA221443; sponsor_name='GILEAD SCIENCES INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260827; submission_class_code=TYPE 4; brand_name=['BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)']
May 22, 2026FDA BLA 761468
BeOne MedicinesFDA novel approval for BEQALZI (NDA 220711, May 13, 2026); 89 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • May 13, 2026 · FDA NDA 220711
    openFDA drugsfda: application_number=NDA220711; sponsor_name='BEONE MEDICINES USA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260513; submission_class_code=TYPE 1; brand_name=['BEQALZI']
May 13, 2026FDA NDA 220711
Corcept TherapeuticsFDA novel approval for LIFYORLI (COPACKAGED) (NDA 220641, Mar 25, 2026); since then posted 37 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Mar 25, 2026 · FDA NDA 220641
    openFDA drugsfda: application_number=NDA220641; sponsor_name='CORCEPT THERAP'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260325; submission_class_code=TYPE 1; brand_name=['LIFYORLI (COPACKAGED)']
Mar 25, 2026FDA NDA 220641
Ascendis PharmaFDA novel approval for YUVIWEL (NDA 219164, Feb 27, 2026); 14 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Feb 27, 2026 · FDA NDA 219164
    openFDA drugsfda: application_number=NDA219164; sponsor_name='ASCENDIS'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260227; submission_class_code=TYPE 1; brand_name=['YUVIWEL']
Feb 27, 2026FDA NDA 219164
OmerosFDA novel approval for YARTEMLEA (BLA 761152, Dec 23, 2025); 11 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Dec 23, 2025 · FDA BLA 761152
    openFDA drugsfda: application_number=BLA761152; sponsor_name='OMEROS CORP'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251223; submission_class_code=TYPE 1; brand_name=['YARTEMLEA']
Dec 23, 2025FDA BLA 761152
CytokineticsFDA novel approval for MYQORZO (NDA 219083, Dec 19, 2025); 49 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Dec 19, 2025 · FDA NDA 219083
    openFDA drugsfda: application_number=NDA219083; sponsor_name='CYTOKINETICS'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251219; submission_class_code=TYPE 1; brand_name=['MYQORZO']
Dec 19, 2025FDA NDA 219083
Arrowhead PharmaceuticalsFDA novel approval for REDEMPLO (NDA 219947, Nov 18, 2025); since then posted 42 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Nov 18, 2025 · FDA NDA 219947
    openFDA drugsfda: application_number=NDA219947; sponsor_name='ARROWHEAD'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251118; submission_class_code=TYPE 1; brand_name=['REDEMPLO']
Nov 18, 2025FDA NDA 219947
Kura OncologyFDA novel approval for KOMZIFTI (NDA 220305, Nov 13, 2025); since then posted 3 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Nov 13, 2025 · FDA NDA 220305
    openFDA drugsfda: application_number=NDA220305; sponsor_name='KURA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251113; submission_class_code=TYPE 1; brand_name=['KOMZIFTI']
Nov 13, 2025FDA NDA 220305
Amneal PharmaceuticalsFDA biosimilar approval for BONCRESA (BLA 761456, Dec 19, 2025; +1 other approval); 78 manufacturing/quality or commercial roles open.
Evidence (3 events)
  • Dec 19, 2025 · FDA BLA 761456
    openFDA drugsfda: application_number=BLA761456; sponsor_name='AMNEAL PHARMS LLC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251219; submission_class_code=UNKNOWN; brand_name=['BONCRESA']
  • Dec 19, 2025 · FDA BLA 761457
    openFDA drugsfda: application_number=BLA761457; sponsor_name='AMNEAL PHARMS LLC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251219; submission_class_code=UNKNOWN; brand_name=['OZILTUS']
  • Jul 9, 2026 · FDA NDA 220790
    openFDA drugsfda: application_number=NDA220790; sponsor_name='AMNEAL'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260709; submission_class_code=TYPE 5; brand_name=['SODIUM BICARBONATE']
Dec 19, 2025FDA BLA 761456
BraccoFDA approval for ISOVUE READI (NDA 220583, Oct 9, 2026); 87 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Oct 9, 2026 · FDA NDA 220583
    openFDA drugsfda: application_number=NDA220583; sponsor_name='BRACCO'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20261009; submission_class_code=TYPE 5; brand_name=['ISOVUE READI']
Oct 9, 2026FDA NDA 220583
BioCryst PharmaceuticalsFDA approval for ORLADEYO (NDA 219776, Dec 11, 2025); 10 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Dec 11, 2025 · FDA NDA 219776
    openFDA drugsfda: application_number=NDA219776; sponsor_name='BIOCRYST'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251211; submission_class_code=TYPE 3; brand_name=['ORLADEYO']
Dec 11, 2025FDA NDA 219776

Device approval + hiring (7)

CompanySignalEvent dateSource
Edwards LifesciencesFDA PMA device approval for Autus Size-Adjustable Valve (P260007, Oct 1, 2026; +1 other approval); 218 manufacturing/quality or commercial roles open.
Evidence (2 events)
  • Oct 1, 2026 · FDA P260007
    openFDA device/pma: pma_number=P260007; supplement_number=(none); applicant='Edwards Lifesciences, LLC'; decision_code=APPR; decision_date=2026-10-01; trade_name='Autus Size-Adjustable Valve'
  • Dec 22, 2025 · FDA P250019
    openFDA device/pma: pma_number=P250019; supplement_number=(none); applicant='Edwards Lifesciences, LLC'; decision_code=APPR; decision_date=2025-12-22; trade_name='SAPIEN M3 Transcatheter Mitral Valve Replacement System'
Oct 1, 2026FDA P260007
FreenomeFDA PMA device approval for SimpleScreen™ CRC (P250029, Jul 24, 2026); since then posted 4 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Jul 24, 2026 · FDA P250029
    openFDA device/pma: pma_number=P250029; supplement_number=(none); applicant='Freenome, LLC'; decision_code=APPR; decision_date=2026-07-24; trade_name='SimpleScreen\x99 CRC'
Jul 24, 2026FDA P250029
NateraFDA PMA device approval for Signatera™ CDx (P260004, May 15, 2026); since then posted 65 manufacturing/quality or commercial roles.
Evidence (1 event)
  • May 15, 2026 · FDA P260004
    openFDA device/pma: pma_number=P260004; supplement_number=(none); applicant='Natera, Inc.'; decision_code=APPR; decision_date=2026-05-15; trade_name='Signatera\x99 CDx'
May 15, 2026FDA P260004
LivaNovaFDA PMA device approval for aura6000™ system (P250013, Mar 18, 2026); 32 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Mar 18, 2026 · FDA P250013
    openFDA device/pma: pma_number=P250013; supplement_number=(none); applicant='LivaNova USA, Inc.'; decision_code=APPR; decision_date=2026-03-18; trade_name='aura6000\x99 system'
Mar 18, 2026FDA P250013
Perimeter Medical Imaging AIFDA PMA device approval for Claire™ OCT System (P250008, Mar 3, 2026); 7 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Mar 3, 2026 · FDA P250008
    openFDA device/pma: pma_number=P250008; supplement_number=(none); applicant='Perimeter Medical Imaging Ai, Inc.'; decision_code=APPR; decision_date=2026-03-03; trade_name='Claire\x99 OCT System'
Mar 3, 2026FDA P250008
BALTFDA PMA device approval for SQUID Liquid Embolic Agent (LEA) (P250009, Jan 30, 2026); since then posted 6 manufacturing/quality or commercial roles.
Evidence (1 event)
  • Jan 30, 2026 · FDA P250009
    openFDA device/pma: pma_number=P250009; supplement_number=(none); applicant='Balt USA, LLC'; decision_code=APPR; decision_date=2026-01-30; trade_name='SQUID Liquid Embolic Agent (LEA)'
Jan 30, 2026FDA P250009
Smith and NephewFDA De Novo device grant for TESSA Spatial Surgery System (DEN250037, Jul 6, 2026); 249 manufacturing/quality or commercial roles open.
Evidence (1 event)
  • Jul 6, 2026 · FDA DEN250037
    openFDA device/510k: k_number=DEN250037; applicant='Smith & Nephew, Inc.'; decision_code=DENG; decision_date=2026-07-06; device_name='TESSA Spatial Surgery System; INTELLIO Tablet (72205455)'
Jul 6, 2026FDA DEN250037

FDA complete response letter (27)

CompanySignalEvent dateSource
Elevar TherapeuticsReceived an FDA complete response letter (NDA 216586, letter dated Jul 9, 2026); 8 roles open.
Evidence (1 event)
  • Jul 9, 2026 · FDA NDA 216586
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Elevar Therapeutics Inc. ATTENTION: Young-Sil (Anna) Yim Executive Director, Regulatory Affairs: Fort Lee, NJ (street omitted) Dear: Young-Sil (Anna) Yim: Please
Jul 9, 2026FDA NDA 216586
Unicycive TherapeuticsReceived an FDA complete response letter (NDA 218607, letter dated Jun 29, 2026).
Evidence (1 event)
  • Jun 29, 2026 · FDA NDA 218607
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Unicycive Therapeutics Inc. Attention: Shalabh Gupta, MD, MPA President & CEO Mountain View, CA (street omitted) Dear Dr. Gupta: Please refer to your new drug
Jun 29, 2026FDA NDA 218607
Evergreen TheragnosticsReceived an FDA complete response letter (NDA 216900, letter dated Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · FDA NDA 216900
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Evergreen Theragnostics, Inc. C/o Bourque Regulatory CMC, Inc. Attention: Mr. Jeffrey Bourque President, Bourque Regulatory CMC, Inc. Springfield, NJ (street omitted) Dear Mr
Jun 26, 2026FDA NDA 216900
Swedish Orphan BiovitrumReceived an FDA complete response letter (BLA 761438, letter dated Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · FDA BLA 761438
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Swedish Orphan Biovitrum AB (publ) Attention: Bao Le US Regulatory Lead, Immunology Waltham, MA (street omitted) Dear Bao Le: Please refer to your biologics license appli
Jun 26, 2026FDA BLA 761438
Tanvex BioPharmaReceived an FDA complete response letter (BLA 761266, letter dated Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · FDA BLA 761266
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Tanvex BioPharma USA, Inc. Attention: Bonnie J. Mills, PhD San Diego, CA (street omitted) Dear Dr. Mills: Please refer to your biologics license application (BLA) dat
Jun 23, 2026FDA BLA 761266
Tris PharmaReceived an FDA complete response letter (NDA 220138, letter dated Jun 15, 2026).
Evidence (1 event)
  • Jun 15, 2026 · FDA NDA 220138
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Tris Pharma, Inc. Attention: Rashmi Aravind Senior Director of Regulatory Affairs Monmouth Junction, NJ (street omitted) Dear Rashmi Aravind: Please refer to your new dr
Jun 15, 2026FDA NDA 220138
Cingulate TherapeuticsReceived an FDA complete response letter (NDA 220283, letter dated May 29, 2026).
Evidence (1 event)
  • May 29, 2026 · FDA NDA 220283
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Cingulate Therapeutics, LLC Attention: Kelly R. Koehn Vice President, Clinical and Regulatory Operations Westwood, KS (street omitted) Dear Kelly Koehn: Please refer to your n
May 29, 2026FDA NDA 220283
Ocuvex TherapeuticsReceived an FDA complete response letter (NDA 217363, letter dated May 15, 2026).
Evidence (1 event)
  • May 15, 2026 · FDA NDA 217363
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Ocuvex Therapeutics, Inc. Attention: Anthony Amato Chief Executive Officer Lee, NJ (street omitted) Dear Anthony Amato: Please refer to your new drug applicati
May 15, 2026FDA NDA 217363
AbbVieReceived an FDA complete response letter (BLA 761459, letter dated Apr 22, 2026); 1155 roles open.
Evidence (1 event)
  • Apr 22, 2026 · FDA BLA 761459
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE AbbVie Inc. Attention: Felipe Martins Associate Director, Regulatory Affairs Irvine, CA (street omitted) Dear Felipe Martins: Please refer to your biologics license applicatio
Apr 22, 2026FDA BLA 761459
Eagle PharmaceuticalsReceived an FDA complete response letter (NDA 220045, letter dated Apr 13, 2026).
Evidence (1 event)
  • Apr 13, 2026 · FDA NDA 220045
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Eagle Pharmaceuticals, Inc. Attention: Janis A. Picurro Senior Vice President, Regulatory Affairs Woodcliff Lake, NJ (street omitted) Dear Janis Picurro: Please ref
Apr 13, 2026FDA NDA 220045
Telix PharmaceuticalsReceived an FDA complete response letter (BLA 761401, letter dated Apr 10, 2026).
Evidence (1 event)
  • Apr 10, 2026 · FDA BLA 761401
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Telix Pharmaceuticals (US) Inc. Attention: Yvonne Chow Global Regulatory Affairs Manager Fishers, IN (street omitted) Dear Yvonne Chow: We refer to your biologics li
Apr 10, 2026FDA BLA 761401
ReplimuneReceived an FDA complete response letter (BL 125827, letter dated Apr 10, 2026); 46 roles open.
Evidence (1 event)
  • Apr 10, 2026 · FDA BL 125827
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE APRIL 10, 2026 Replimune, Inc. Attention: Kari Jeschke Woburn, MA (street omitted) Dear Kari Jeschke: Please refer to your Biologics License Application (BLA) received (1
Apr 10, 2026FDA BL 125827
Aldeyra Therapeutics, Inc.Received an FDA complete response letter (NDA 216442, letter dated Mar 16, 2026).
Evidence (1 event)
  • Mar 16, 2026 · FDA NDA 216442
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Aldeyra Therapeutics, Inc. Attention: David Noskowitz Regulatory Affairs Consultant Lexington, MA (street omitted) Dear David Noskowitz: Please refer to your new dr
Mar 16, 2026FDA NDA 216442
Fresenius KabiReceived an FDA complete response letter (NDA 215818, letter dated Feb 27, 2026).
Evidence (1 event)
  • Feb 27, 2026 · FDA NDA 215818
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Fresenius Kabi USA, LLC Attention: Jennifer Gross, MS Senior Regulatory Affairs Associate Lake Zurich, IL (street omitted) Dear Jennifer Gross: Please refer to your new dr
Feb 27, 2026FDA NDA 215818
Ferring PharmaceuticalsReceived an FDA complete response letter (BLA 761253, letter dated Feb 27, 2026); 61 roles open.
Evidence (1 event)
  • Feb 27, 2026 · FDA BLA 761253
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Ferring Pharmaceuticals Inc. Attention: Sangeeta Chavan Patil Director, Regulatory Affairs Parsippany, NJ (street omitted) Dear Sangeeta Chavan Patil: Please refer to your
Feb 27, 2026FDA BLA 761253
Fresenius KabiReceived an FDA complete response letter (NDA 214610, letter dated Feb 27, 2026).
Evidence (1 event)
  • Feb 27, 2026 · FDA NDA 214610
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Fresenius Kabi USA, LLC Attention: Jennifer Gross, M.S. Senior Regulatory Affairs Associate Lake Zurich, IL (street omitted) Dear Jennifer Gross: Please refer to your new
Feb 27, 2026FDA NDA 214610
Amphastar PharmaceuticalsReceived an FDA complete response letter (BLA 761403, letter dated Feb 26, 2026).
Evidence (1 event)
  • Feb 26, 2026 · FDA BLA 761403
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Amphastar Pharmaceuticals, Inc. Attention: Magda Albedrop, RAC-Drugs Senior Supervisor of the CMC and Submissions Group Regulatory Affairs Rancho Cucamonga, CA (street omitted)
Feb 26, 2026FDA BLA 761403
Disc MedicineReceived an FDA complete response letter (NDA 220707, letter dated Feb 13, 2026).
Evidence (1 event)
  • Feb 13, 2026 · FDA NDA 220707
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Disc Medicine, Inc. Attention: Steve Caffé, MD Chief Regulatory Officer Watertown, MA (street omitted) Dear Dr. Caffé: Please refer to your new drug application (N
Feb 13, 2026FDA NDA 220707
REGENXBIO Inc.Received an FDA complete response letter (BL 125840, letter dated Feb 7, 2026); 12 roles open.
Evidence (1 event)
  • Feb 7, 2026 · FDA BL 125840
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE February 7, 2026 REGENXBIO, Inc. Attention: Steve Pakola, MD Rockville, MD (street omitted) Dear Dr. Pakola: Please refer to your Biologics License Application (1b) (4
Feb 7, 2026FDA BL 125840
Aquestive TherapeuticsReceived an FDA complete response letter (NDA 219870, letter dated Jan 30, 2026).
Evidence (1 event)
  • Jan 30, 2026 · FDA NDA 219870
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Aquestive Therapeutics Inc. Attention: Melina Cioffi, PharmD Vice President, Regulatory Affairs Warren, NJ (street omitted) Dear Dr. Cioffi: Please refer to your new drug ap
Jan 30, 2026FDA NDA 219870
Outlook TherapeuticsReceived an FDA complete response letter (BLA 761320, letter dated Dec 30, 2025).
Evidence (1 event)
  • Dec 30, 2025 · FDA BLA 761320
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Outlook Therapeutics, Inc. Attention: Jennifer Kissner, PhD Executive Vice President Iselin, NJ (street omitted) Dear Dr. Kissner: Please refer to your biologics
Dec 30, 2025FDA BLA 761320
Corcept TherapeuticsReceived an FDA complete response letter (NDA 219398, letter dated Dec 30, 2025; corrected letter issued Jan 28, 2026); 84 roles open.
Evidence (1 event)
  • Dec 30, 2025 · FDA NDA 219398
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Corcept Therapeutics Attention: Christopher Golis Vice President, Quality Assurance & Regulatory Affairs Redwood City, CA (street omitted) Dear Christopher Golis: Ple
Dec 30, 2025FDA NDA 219398
GSKReceived an FDA complete response letter (BLA 761458, letter dated Dec 16, 2025).
Evidence (1 event)
  • Dec 16, 2025 · FDA BLA 761458
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE GlaxoSmithKline LLC Attention: David Colton Director, Global Regulatory Affairs Cambridge, MA (street omitted) Dear David Colton: Please refer to your biolog
Dec 16, 2025FDA BLA 761458
LIB TherapeuticsReceived an FDA complete response letter (BLA 761427, letter dated Dec 12, 2025).
Evidence (1 event)
  • Dec 12, 2025 · FDA BLA 761427
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE LIB Therapeutics, Inc. Attention: Evan A. Stein, MD, PhD Chief Executive and Scientific Officer Cincinnati, OH (street omitted) Dear Dr. Stein: Please refer to your biologics l
Dec 12, 2025FDA BLA 761427
SandozReceived an FDA complete response letter (BLA 761271, letter dated Dec 9, 2025).
Evidence (1 event)
  • Dec 9, 2025 · FDA BLA 761271
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Sandoz Inc. Attention: Raheel Khan, MBA, RAC Associate Director, Global Regulatory Affairs Princeton, NJ (street omitted) Dear Raheel Khan: submission. We acknowledge rece
Dec 9, 2025FDA BLA 761271
BiohavenReceived an FDA complete response letter (NDA 210862, letter dated Nov 4, 2025).
Evidence (1 event)
  • Nov 4, 2025 · FDA NDA 210862
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Biohaven Therapeutics, Ltd. c/o Biohaven Pharmaceuticals, Inc. Attention: Marianne Frost, MA Senior VP, Regulatory Affairs and Operations New Haven, CT (street omitted) Dear M
Nov 4, 2025FDA NDA 210862
GSKReceived an FDA complete response letter (BLA 761440, letter dated Oct 23, 2025).
Evidence (1 event)
  • Oct 23, 2025 · FDA BLA 761440
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE GlaxoSmithKline LLC Attention: Hayley Karpick, PharmD, RPh Associate Director, Global Regulatory Affairs Collegeville, PA (street omitted) Dear Dr. Karpick
Oct 23, 2025FDA BLA 761440
Feedback